Embodiments described herein relate to apparatuses, systems, and methods the treatment of wounds, for example using dressings in combination with negative pressure wound therapy.
The treatment of open or chronic wounds that are too large to spontaneously close or otherwise fail to heal by means of applying negative pressure to the site of the wound is well known in the art. Negative pressure wound therapy (NPWT) systems currently known in the art commonly involve placing a cover that is impermeable or semi-permeable to fluids over the wound, using various means to seal the cover to the tissue of the patient surrounding the wound, and connecting a source of negative pressure (such as a vacuum pump) to the cover in a manner so that negative pressure is created and maintained under the cover. It is believed that such negative pressures promote wound healing by facilitating the formation of granulation tissue at the wound site and assisting the body's normal inflammatory process while simultaneously removing excess fluid, which may contain adverse cytokines and/or bacteria. However, further improvements in NPWT are needed to fully realize the benefits of treatment.
Many different types of wound dressings are known for aiding in NPWT systems. These different types of wound dressings include many different types of materials and layers, for example, gauze, pads, foam pads or multi-layer wound dressings. One example of a multi-layer wound dressing is the PICO dressing, available from Smith & Nephew, which includes a superabsorbent layer beneath a backing layer to provide a canister-less system for treating a wound with NPWT. The wound dressing may be sealed to a suction port providing connection to a length of tubing, which may be used to pump fluid out of the dressing and/or to transmit negative pressure from a pump to the wound dressing.
Prior art dressings for use in negative pressure such as those described above have included a negative pressure source located in a remote location from the wound dressing. Negative pressure sources located remote from the wound dressing have to be held by or attached to the user or other pump support mechanism. Additionally, a tubing or connector is required to connect the remote negative pressure source to the wound dressing. The remote pump and tubing can be cumbersome and difficult to hide in or attach to patient clothing. Depending on the location of the wound dressing, it can be difficult to comfortably and conveniently position the remote pump and tubing. When used, wound exudate may soak into the dressing, and the moisture from the wound has made it difficult to incorporate electronic components into the dressing.
Embodiments of the present disclosure relate to apparatuses and methods for wound treatment. Some of the wound treatment apparatuses described herein comprise a negative pressure source or a pump system for providing negative pressure to a wound. Wound treatment apparatuses may also comprise wound dressings that may be used in combination with the negative pressure sources and pump assemblies described herein. In some embodiments, a negative pressure source is incorporated into a wound dressing apparatus so that the wound dressing and the negative pressure source are part of an integral or integrated wound dressing structure that applies the wound dressing and the negative pressure source simultaneously to a patient's wound. The negative pressure source and/or electronic components may be positioned between a wound contact layer and a cover layer of the wound dressing. An electronics assembly can be incorporated into the absorbent material of the dressing to prevent pooling of wound exudate and maintain conformability of the dressing. These and other embodiments as described herein are directed to overcoming particular challenges involved with incorporating a negative pressure source and/or electronic components into a wound dressing.
According to one embodiment, a wound dressing apparatus can comprise a wound contact layer, the wound contact layer can comprise a proximal wound-facing face and a distal face, wherein the proximal wound-facing face is configured to be positioned in contact with a wound, a spacer layer comprising a proximal wound-facing face and a distal face, the spacer layer positioned over the distal face of the wound contact layer, an absorbent layer positioned on the distal face of the spacer layer, an electronics unit comprising a negative pressure source and/or electronic components, wherein the absorbent layer comprises a recess configured to receive the electronics unit and the absorbent layer is configured to be in fluid communication with the electronics unit and a cover layer configured to cover and form a seal over the wound contact layer, the spacer layer, the absorbent layer, and the electronics unit.
The wound dressing apparatus of the preceding paragraph or in other embodiments can include one or more of the following features. The electronic components can comprise one or more of a power source, a flexible circuit board, a sensor, a switch, and/or a light or LED indicator. The wound dressing further can comprise a negative pressure source inlet protection mechanism and a negative pressure source outlet or exhaust. The negative pressure source outlet or exhaust can comprises an antibacterial membrane and/or a non-return valve. The cover layer can comprise an aperture over the outlet or exhaust. The negative pressure source inlet protection mechanism can comprise a hydrophobic material configured to prevent fluid from entering the negative pressure source.
Any of the features, components, or details of any of the arrangements or embodiments disclosed in this application, including without limitation any of the pump embodiments and any of the negative pressure wound therapy embodiments disclosed below, are interchangeably combinable with any other features, components, or details of any of the arrangements or embodiments disclosed herein to form new arrangements and embodiments.
Embodiments disclosed herein relate to apparatuses and methods of treating a wound with reduced pressure, including a source of negative pressure and wound dressing components and apparatuses. The apparatuses and components comprising the wound overlay and packing materials, if any, are sometimes collectively referred to herein as dressings.
It will be appreciated that throughout this specification reference is made to a wound. It is to be understood that the term wound is to be broadly construed and encompasses open and closed wounds in which skin is torn, cut or punctured or where trauma causes a contusion, or any other superficial or other conditions or imperfections on the skin of a patient or otherwise that benefit from reduced pressure treatment. A wound is thus broadly defined as any damaged region of tissue where fluid may or may not be produced. Examples of such wounds include, but are not limited to, abdominal wounds or other large or incisional wounds, either as a result of surgery, trauma, sternotomies, fasciotomies, or other conditions, dehisced wounds, acute wounds, chronic wounds, subacute and dehisced wounds, traumatic wounds, flaps and skin grafts, lacerations, abrasions, contusions, burns, diabetic ulcers, pressure ulcers, stoma, surgical wounds, trauma and venous ulcers or the like.
It will be understood that embodiments of the present disclosure are generally applicable to use in topical negative pressure (“TNP”) therapy systems. Briefly, negative pressure wound therapy assists in the closure and healing of many forms of “hard to heal” wounds by reducing tissue oedema; encouraging blood flow and granular tissue formation; removing excess exudate and may reduce bacterial load (and thus infection risk). In addition, the therapy allows for less disturbance of a wound leading to more rapid healing. TNP therapy systems may also assist on the healing of surgically closed wounds by removing fluid and by helping to stabilize the tissue in the apposed position of closure. A further beneficial use of TNP therapy can be found in grafts and flaps where removal of excess fluid is important and close proximity of the graft to tissue is required in order to ensure tissue viability.
As is used herein, reduced or negative pressure levels, such as −X mmHg, represent pressure levels relative to normal ambient atmospheric pressure, which can correspond to 760 mmHg (or 1 atm, 29.93 inHg, 101.325 kPa, 14.696 psi, etc.). Accordingly, a negative pressure value of −X mmHg reflects absolute pressure that is X mmHg below 760 mmHg or, in other words, an absolute pressure of (760-X) mmHg. In addition, negative pressure that is “less” or “smaller” than X mmHg corresponds to pressure that is closer to atmospheric pressure (e.g., −40 mmHg is less than −60 mmHg). Negative pressure that is “more” or “greater” than −X mmHg corresponds to pressure that is further from atmospheric pressure (e.g., −80 mmHg is more than −60 mmHg). In some embodiments, local ambient atmospheric pressure is used as a reference point, and such local atmospheric pressure may not necessarily be, for example, 760 mmHg.
The negative pressure range for some embodiments of the present disclosure can be approximately −80 mmHg, or between about −20 mmHg and −200 mmHg. Note that these pressures are relative to normal ambient atmospheric pressure, which can be 760 mmHg. Thus, −200 mmHg would be about 560 mmHg in practical terms. In some embodiments, the pressure range can be between about −40 mmHg and −150 mmHg. Alternatively a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also in other embodiments a pressure range of below −75 mmHg can be used. Alternatively, a pressure range of over approximately −100 mmHg, or even −150 mmHg, can be supplied by the negative pressure apparatus.
In some embodiments of wound closure devices described herein, increased wound contraction can lead to increased tissue expansion in the surrounding wound tissue. This effect may be increased by varying the force applied to the tissue, for example by varying the negative pressure applied to the wound over time, possibly in conjunction with increased tensile forces applied to the wound via embodiments of the wound closure devices. In some embodiments, negative pressure may be varied over time for example using a sinusoidal wave, square wave, and/or in synchronization with one or more patient physiological indices (e.g., heartbeat). Examples of such applications where additional disclosure relating to the preceding may be found include U.S. Pat. No. 8,235,955, titled “Wound treatment apparatus and method,” issued on Aug. 7, 2012; and U.S. Pat. No. 7,753,894, titled “Wound cleansing apparatus with stress,” issued Jul. 13, 2010. The disclosures of both of these patents are hereby incorporated by reference in their entirety.
International Application PCT/GB 2012/000587, titled “WOUND DRESSING AND METHOD OF TREATMENT” and filed on Jul. 12, 2012, and published as WO 2013/007973 A2 on Jan. 17, 2013, is an application, hereby incorporated by reference in its entirety herein, that is directed to embodiments, methods of manufacture, and wound dressing components and wound treatment apparatuses that may be used in combination or in addition to the embodiments described herein. Additionally, embodiments of the wound dressings, wound treatment apparatuses and methods described herein may also be used in combination or in addition to those described in International Application No. PCT/IB2013/001469, filed May 22, 2013, titled “APPARATUSES AND METHODS FOR NEGATIVE PRESSURE WOUND THERAPY,” published as WO 2013/175306 on Nov. 28, 2013, U.S. patent application Ser. No. 14/418,874, filed Jan. 30, 2015, published as U.S. Publication No. 2015/0216733, published Aug. 6, 2015, titled “WOUND DRESSING AND METHOD OF TREATMENT,” U.S. patent application Ser. No. 14/418,908, filed Jan. 30, 2015, published as U.S. Publication No. 2015/0190286, published Jul. 9, 2015, titled “WOUND DRESSING AND METHOD OF TREATMENT,” U.S. patent application Ser. No. 14/658,068, filed Mar. 13, 2015, U.S. Application No. 2015/0182677, published Jul. 2, 2015, titled “WOUND DRESSING AND METHOD OF TREATMENT,” the disclosures of which are hereby incorporated by reference in their entireties. Embodiments of the wound dressings, wound treatment apparatuses and methods described herein may also be used in combination or in addition to those described in U.S. patent application Ser. No. 13/092,042, filed Apr. 21, 2011, published as U.S. 2011/0282309, titled “WOUND DRESSING AND METHOD OF USE,” and which is hereby incorporated by reference in its entirety, including further details relating to embodiments of wound dressings, the wound dressing components and principles, and the materials used for the wound dressings.
Embodiments of the wound dressings, wound treatment apparatuses and methods described herein relating to wound dressings with electronics incorporated into the dressing may also be used in combination or in addition to those described in International Application PCT/EP2017/055225, filed Mar. 6, 2017, titled “WOUND TREATMENT APPARATUSES AND METHODS WITH NEGATIVE PRESSURE SOURCE INTEGRATED INTO WOUND DRESSING,” and which is hereby incorporated by reference in its entirety, including further details relating to embodiments of wound dressings, the wound dressing components and principles, and the materials used for the wound dressings.
In some embodiments, a source of negative pressure (such as a pump) and some or all other components of the TNP system, such as power source(s), sensor(s), connector(s), user interface component(s) (such as button(s), switch(es), speaker(s), screen(s), etc.) and the like, can be integral with the wound dressing. The wound dressing can include various material layers described here and described in further detail in International Application No. PCT/EP2017/055225, filed Mar. 6, 2017, entitled WOUND TREATMENT APPARATUSES AND METHODS WITH NEGATIVE PRESSURE SOURCE INTEGRATED INTO WOUND DRESSING. The material layers can include a wound contact layer, one or more absorbent layers, one or more spacer or transmission layers, and a backing layer or cover layer covering the one or more absorbent and spacer or transmission layers. The wound dressing can be placed over a wound and sealed to the wound with the pump and/or other electronic components contained under the cover layer within the wound dressing. In some embodiments, the dressing can be provided as a single article with all wound dressing elements (including the pump) pre-attached and integrated into a single unit. In some embodiments, a periphery of the wound contact layer can be attached to the periphery of the cover layer enclosing all wound dressing elements as illustrated in
In some embodiments, the pump and/or other electronic components can be configured to be positioned adjacent to or next to the absorbent and/or transmission layers so that the pump and/or other electronic components are still part of a single article to be applied to a patient. In some embodiments, with the pump and/or other electronics positioned away from the wound site.
The dressing can comprise a wound contact layer 110, a transmission layer 111, an absorbent layer 112, a moisture vapor permeable film or cover layer 113, 113 positioned above the wound contact layer, transmission layer, absorbent layer, or other layers of the dressing. The wound contact layer can be configured to be in contact with the wound. The wound contact layer can include an adhesive on the patient facing side for securing the dressing to the surrounding skin or on the top side for securing the wound contact layer to a cover layer or other layer of the dressing. In operation, the wound contact layer can be configured to provide unidirectional flow so as to facilitate removal of exudate from the wound while blocking or substantially preventing exudate from returning to the wound.
The wound contact layer 110 can be a polyurethane layer or polyethylene layer or other flexible layer which is perforated, for example via a hot pin process, laser ablation process, ultrasound process or in some other way or otherwise made permeable to liquid and gas. The wound contact layer 110 has a lower surface and an upper surface. The perforations preferably comprise through holes in the wound contact layer 110 which enable fluid to flow through the layer 110. The wound contact layer 110 helps prevent tissue ingrowth into the other material of the wound dressing. Preferably, the perforations are small enough to meet this requirement while still allowing fluid to flow therethrough. For example, perforations formed as slits or holes having a size ranging from 0.025 mm to 1.2 mm are considered small enough to help prevent tissue ingrowth into the wound dressing while allowing wound exudate to flow into the dressing. In some configurations, the wound contact layer 110 may help maintain the integrity of the entire dressing 100 while also creating an air tight seal around the absorbent pad in order to maintain negative pressure at the wound.
Some embodiments of the wound contact layer 110 may also act as a carrier for an optional lower and upper adhesive layer (not shown). For example, a lower pressure sensitive adhesive may be provided on the lower surface of the wound dressing 100 whilst an upper pressure sensitive adhesive layer may be provided on the upper surface of the wound contact layer. The pressure sensitive adhesive, which may be a silicone, hot melt, hydrocolloid or acrylic based adhesive or other such adhesives, may be formed on both sides or optionally on a selected one or none of the sides of the wound contact layer. When a lower pressure sensitive adhesive layer is utilized it may be helpful to adhere the wound dressing 100 to the skin around a wound site. In some embodiments, the wound contact layer may comprise perforated polyurethane film. The lower surface of the film may be provided with a silicone pressure sensitive adhesive and the upper surface may be provided with an acrylic pressure sensitive adhesive, which may help the dressing maintain its integrity. In some embodiments, a polyurethane film layer may be provided with an adhesive layer on both its upper surface and lower surface, and all three layers may be perforated together.
A layer 111 of porous or transmission material can be located above the wound contact layer 110. As used herein, the terms porous material, spacer, and/or transmission layer can be used interchangeably to refer to the layer of material in the dressing configured to distribute negative pressure throughout the wound area. This porous layer, or transmission layer, 111 allows transmission of fluid including liquid and gas away from a wound site into upper layers of the wound dressing. In particular, the transmission layer 111 preferably ensures that an open air channel can be maintained to communicate negative pressure over the wound area even when the absorbent layer has absorbed substantial amounts of exudates. The layer 111 should preferably remain open under the typical pressures that will be applied during negative pressure wound therapy as described above, so that the whole wound site sees an equalized negative pressure. The layer 111 may be formed of a material having a three dimensional structure. For example, a knitted or woven spacer fabric (for example Baltex 7970 weft knitted polyester) or a non-woven fabric could be used.
The transmission layer assists in distributing negative pressure over the wound site and facilitating transport of wound exudate and fluids into the wound dressing. In some embodiments, the transmission layer can be formed at least partially from a three dimensional (3D) fabric.
In some embodiments, the transmission layer 111 comprises a 3D polyester spacer fabric layer including a top layer (that is to say, a layer distal from the wound-bed in use) which is a 84/144 textured polyester, and a bottom layer (that is to say, a layer which lies proximate to the wound bed in use) which is a 10 denier flat polyester and a third layer formed sandwiched between these two layers which is a region defined by a knitted polyester viscose, cellulose or the like monofilament fiber. Other materials and other linear mass densities of fiber could of course be used.
Whilst reference is made throughout this disclosure to a monofilament fiber it will be appreciated that a multistrand alternative could of course be utilized. The top spacer fabric thus has more filaments in a yarn used to form it than the number of filaments making up the yarn used to form the bottom spacer fabric layer.
This differential between filament counts in the spaced apart layers helps control moisture flow across the transmission layer. Particularly, by having a filament count greater in the top layer, that is to say, the top layer is made from a yarn having more filaments than the yarn used in the bottom layer, liquid tends to be wicked along the top layer more than the bottom layer. In use, this differential tends to draw liquid away from the wound bed and into a central region of the dressing where the absorbent layer 112 helps lock the liquid away or itself wicks the liquid onwards towards the cover layer 113 where it can be transpired.
Preferably, to improve the liquid flow across the transmission layer 111 (that is to say perpendicular to the channel region formed between the top and bottom spacer layers), the 3D fabric may be treated with a dry cleaning agent (such as, but not limited to, Perchloro Ethylene) to help remove any manufacturing products such as mineral oils, fats or waxes used previously which might interfere with the hydrophilic capabilities of the transmission layer. In some embodiments, an additional manufacturing step can subsequently be carried in which the 3D spacer fabric is washed in a hydrophilic agent (such as, but not limited to, Feran Ice 30 g/l available from the Rudolph Group). This process step helps ensure that the surface tension on the materials is so low that liquid such as water can enter the fabric as soon as it contacts the 3D knit fabric. This also aids in controlling the flow of the liquid insult component of any exudates.
Further, an absorbent layer (such as layer 112) for absorbing and retaining exudate aspirated from the wound can be utilized. In some embodiments, a superabsorbent material can be used in the absorbent layer 112. In some embodiments, the absorbent includes a shaped form of a superabsorber layer.
A layer 112 of absorbent material is provided above the transmission layer 111. The absorbent material, which comprise a foam or non-woven natural or synthetic material, and which may optionally comprise a super-absorbent material, forms a reservoir for fluid, particularly liquid, removed from the wound site. In some embodiments, the layer 111 may also aid in drawing fluids towards the cover layer 113.
The material of the absorbent layer 112 may also prevent liquid collected in the wound dressing from flowing freely within the dressing, and preferably acts so as to contain any liquid collected within the dressing. The absorbent layer 112 also helps distribute fluid throughout the layer via a wicking action so that fluid is drawn from the wound site and stored throughout the absorbent layer. This helps prevent agglomeration in areas of the absorbent layer. The capacity of the absorbent material must be sufficient to manage the exudates flow rate of a wound when negative pressure is applied. Since in use the absorbent layer experiences negative pressures the material of the absorbent layer is chosen to absorb liquid under such circumstances. A number of materials exist that are able to absorb liquid when under negative pressure, for example superabsorber material. The absorbent layer 112 may typically be manufactured from ALLEVYN™ foam, Freudenberg 114-224-4 or Chem-Posite™ 11C-450. In some embodiments, the absorbent layer 112 may comprise a composite comprising superabsorbent powder, fibrous material such as cellulose, and bonding fibers. In a preferred embodiment, the composite is an airlaid, thermally-bonded composite.
In some embodiments, the absorbent layer 112 is a layer of non-woven cellulose fibers having super-absorbent material in the form of dry particles dispersed throughout. Use of the cellulose fibers introduces fast wicking elements which help quickly and evenly distribute liquid taken up by the dressing. The juxtaposition of multiple strand-like fibers leads to strong capillary action in the fibrous pad which helps distribute liquid. In this way, the super-absorbent material is efficiently supplied with liquid. The wicking action also assists in bringing liquid into contact with the upper cover layer to aid increase transpiration rates of the dressing.
The wound dressing layers of the electronics area and the absorbent layer can be covered by one continuous cover layer or backing layer 113. As used herein, the terms cover layer and/or backing layer can be used interchangeably to refer to the layer of material in the dressing configured to cover the underlying dressing layers and seal to the wound contact layer and/or the skin surrounding the wound. In some embodiments, the cover layer can include a moisture vapor permeable material that prevents liquid exudate removed from the wound and other liquids from passing through, while allowing gases through.
The cover layer 113 is preferably gas impermeable, but moisture vapor permeable, and can extend across the width of the wound dressing 100. The cover layer 113, which may for example be a polyurethane film (for example, Elastollan SP9109) having a pressure sensitive adhesive on one side, is impermeable to gas and this layer thus operates to cover the wound and to seal a wound cavity over which the wound dressing is placed. In this way an effective chamber is made between the cover layer 113 and a wound site where a negative pressure can be established. The cover layer 113 is preferably sealed to the wound contact layer 110 in a border region around the circumference of the dressing, ensuring that no air is drawn in through the border area, for example via adhesive or welding techniques. The cover layer 113 protects the wound from external bacterial contamination (bacterial barrier) and allows liquid from wound exudates to be transferred through the layer and evaporated from the film outer surface. The cover layer 113 preferably comprises two layers; a polyurethane film and an adhesive pattern spread onto the film. The polyurethane film is preferably moisture vapor permeable and may be manufactured from a material that has an increased water transmission rate when wet. In some embodiments, the moisture vapor permeability of the cover layer increases when the cover layer becomes wet. The moisture vapor permeability of the wet cover layer may be up to about ten times more than the moisture vapor permeability of the dry cover layer.
The electronics area 161 can include a source of negative pressure (such as a pump) and some or all other components of the TNP system, such as power source(s), sensor(s), connector(s), user interface component(s) (such as button(s), switch(es), speaker(s), screen(s), etc.) and the like, that can be integral with the wound dressing. For example, the electronics area 161 can include a button or switch 114 as shown in
The absorbent area 160 can include an absorbent material 112 and can be positioned over the wound site. The electronics area 161 can be positioned away from the wound site, such as by being located off to the side from the absorbent area 160. The electronics area 161 can be positioned adjacent to and in fluid communication with the absorbent area 160 as shown in
In some embodiments, additional layers of dressing material can be included in the electronics area 161, the absorbent area 160, or both areas. In some embodiments, the dressing can comprise one or more transmission layers and/or one or more absorbent layer positioned above the wound contact layer 110 and below the cover layer 113 of the dressing.
In some embodiments, the electronics area 161 of the dressing can comprise electronic components 150. In some embodiments, the electronics area 161 of the dressing can comprise a plurality of layers of transmission material and/or absorbent material and electronic components 150 can be embedded within the plurality of layers of transmission material and/or absorbent material. The layers of transmission or absorbent material can have recesses or cut outs to embed the electronic components 150 within whilst providing structure to prevent collapse. The electronic components 150 can include a pump, power source, controller, and/or an electronics package.
A pump exhaust can be provided to exhaust air from the pump to the outside of the dressing. The pump exhaust can be in communication with the electronics area 161 and the outside of the dressing.
As used herein the upper layer, top layer, or layer above refers to a layer furthest from the surface of the skin or wound while the dressing is in use and positioned over the wound. Accordingly, the lower surface, lower layer, bottom layer, or layer below refers to the layer that is closest to the surface of the skin or wound while the dressing is in use and positioned over the wound. Additionally, the layers can have a proximal wound-facing face referring to a side or face of the layer closest to the skin or wound and a distal face referring to a side or face of the layer furthest from the skin or wound.
The electronics area 161 can include an electronics unit 150 positioned below the cover layer 113 of the dressing. In some embodiments, the electronics unit can be surrounded by a material to enclose or encapsulate a negative pressure source and electronics components by surrounding the electronics. In some embodiments, this material can be a casing. In some embodiments, the electronics unit can be encapsulated or surrounded by a protective coating, for example, a hydrophobic coating as described herein. The electronics unit can be in contact with the dressing layers in the absorbent area 160 and covered by the cover layer 113. As used herein, the electronics unit includes a lower or wound facing surface that is closest to the wound and an opposite, upper surface, furthest from the wound when the wound dressing is placed over a wound.
As illustrated in
The electronics unit 267 can also include one or more vents or exhausts 264 for the pump outlet. However, the vent or exhaust 264 is positioned at the outlet of the pump and extending to the upper surface of the electronics unit. As shown in
In some embodiments, the upper surface of the electronics unit can include one or more indicators 266 for indicating a condition of the pump and/or level of pressure within the dressing. The indicators can be small LED lights or other light source that are visible through the dressing material or through holes in the dressing material above the indicators. The indicators can be green, yellow, red, orange, or any other color. For example, there can be two lights, one green light and one orange light. The green light can indicate the device is working properly and the orange light can indicate that there is some issue with the pump (e.g. dressing leak, saturation level of the dressing, and/or low battery).
The batteries 268 can be in electrical communication with a flexible circuit board 276. In some embodiments, one or more battery connections are connected to a surface of the flexible circuit board 276. In some embodiments, the flexible circuit board can have other electronics incorporated within. For example, the flexible circuit board may have various sensors including, but not limited to, one or more pressure sensors, temperature sensors, optic sensors and/or cameras, and/or saturation indicators.
In such embodiments, the components of the electronics unit 267 may include a protective coating to protect the electronics from the fluid within the dressing. The coating can provide a means of fluid separation between the electronics unit 267 and the absorbent materials of the dressing. The coating can be a hydrophobic coating including, but not limited to, a silicone coating or polyurethane coating. The pump inlet component can be used to protect the pump from fluid on the inlet and the pump outlet mechanism can include a non-return valve that protects fluid from entering the outlet as described in more detail with reference to PCT International Application No. PCT/EP2017/055225, filed Mar. 6, 2017, titled WOUND TREATMENT APPARATUSES AND METHODS WITH NEGATIVE PRESSURE SOURCE INTEGRATED INTO WOUND DRESSING and PCT International Application No. PCT/EP2017/059883, filed Apr. 26, 2017, titled WOUND DRESSINGS AND METHODS OF USE WITH INTEGRATED NEGATIVE PRESSURE SOURCE HAVING A FLUID INGRESS INHIBITION COMPONENT, which are hereby incorporated by reference in their entireties.
The electronics unit 267 includes one or more slits, grooves or recesses 271 in the unit between the pump and the two batteries. The slits, grooves or recesses 271 can allow for the electronics unit 267 to be flexible and conform to the shape of the wound. The unit 267 can have two parallel slits, grooves or recesses 271 forming three segments of the electronics unit 267. The slits, grooves or recesses 271 of the unit 267 create hinge points or gaps that allows for flexibility of the electronics unit at that hinge point. The pump exhaust vents 264, switch 265, and indicator 266 are shown on the top surface surrounded by the electronics unit 267. As illustrated, one embodiment of the electronics unit 267 has two hinge points to separate the unit into three regions or panels, for example one to contain one battery, one to contain the pump, and one to contain another battery. In some embodiments, the slits, grooves or recesses may extend parallel with a longitudinal axis of the dressing that extends along the length of the dressing through the electronics area of the dressing through the absorbent area of the dressing.
In some embodiments, the absorbent components and electronics components can be overlapping but offset. For example, a portion of the electronics area can overlap the absorbent area, for example overlapping the superabsorber layer, but the electronics area is not completely over the absorbent area. Therefore, a portion of the electronics area can be offset from the absorbent area. The dressing layer and electronic components can be enclosed in a wound contact layer 304 positioned below the lower most layer and a cover layer (not shown) positioned above the absorbent layer and electronics. The wound contact layer and cover layer can be sealed at a perimeter enclosing the dressing components. In some embodiments, the cover layer can be in direct physical contact with the absorbent material, and/or the electronics unit. In some embodiments, the cover layer can be sealed to a portion of the electronics unit and/or casing, for example, in areas where holes or apertures are used to accommodate the electronic components (e.g. a switch and/or exhaust).
The wound dressing of
The wound dressing can include an electronics label or covering 541 positioned over the aperture 540 in the overlay layer 517. In some embodiments, the label or covering 541 can be positioned under the cover layer 513. In other embodiments, the cover layer 513 can be positioned below the label and can also have an aperture to allow the label or covering 541 to communicate with the underlying electronic components.
A first layer of apertured absorbent material 651 can be provided over the transmission layer 611. The first apertured absorbent layer 651 can include an aperture 629. In some embodiments, the aperture 629 can be sized and shaped to fit the electronics unit 650 therein. The first apertured absorbent layer 651 can be sized and shaped to the size of the electronics area and does not extend into the absorbent area. In some embodiments, the apertures 629 can be shaped and sized to fit the individual components of the electronics unit 650.
A second apertured absorbent layer 622 can be provided over the first absorbent layer 651. In some embodiments, the second absorbent layer 622 include apertures 628. The second absorbent layer 622 can be sized and shaped to the size of the electronics area and absorbent area. In some embodiments, the apertures 628 can be shaped and sized to fit the individual components of the electronics unit 650.
An electronics unit 650 can be positioned in the apertures 628 and 629 of the first and second apertured absorbent material 651 and 622. The electronics unit 650 can include a pump 627, power source 626, and a printed circuit board 681. In some embodiments, the pump 627 can include a pump inlet mechanism 1710 and an outlet mechanism 682. In some embodiments, the printed circuit board 681 can include electronics including but not limited to a switch, sensors, and LEDs as described herein. In some embodiments, the circuit board 681 can include one or more hole to be positioned over one or more exhaust vents (not shown) in the outlet mechanism 682 as described in more detail herein.
An overlay layer 617 can be provided over the electronics components 650 and absorbent layer 622. In some embodiments, the overlay layer 617 can be one or more layers of absorbent and/or transmission material as described herein. In some embodiments, the overlay layer 617 can comprise a conformable material overlaying and overbordering the perimeter of the lower layers of transmission and absorbent materials. In some embodiments, the overlay layer 617 can soften the edges of the wound dressing layers by decreasing the profile around the edges of the dressing layers. In some embodiments, the overlay layer 617 can be provided to protect the cover layer from being punctured by the lower layers when positioned over the dressing layers as described in more details below. The overlay layer 617 can include an aperture 671 to allow access to at least a portion of the electronics unit 650 positioned below.
A cover layer or backing layer 613 can be positioned over the overlay layer 617. In some embodiments, when the overlay layer 617 is not used, the cover layer or backing layer 613 can be provided above absorbent layers 622, and/or electronic components 650. The cover layer 613 can form a seal to the wound contact layer 610 at a perimeter region enclosing the overlay layer 617, absorbent layers 622 and 651, electronic components 650, and the transmission layer 611. In some embodiments, the cover layer 613 can be a flexible sheet of material that forms and molds around the dressing components when they are applied to the wound. In other embodiments, the cover layer 613 can be a material that is preformed or premolded to fit around the dressing components as shown in
In some embodiments, the cover layer or backing layer 613 can include an aperture 672. The aperture 672 can be positioned over at least a portion of the aperture 671 in the overlay layer 617 to allow access to at least a portion of the electronics unit 650 positioned below. In some embodiments, the apertures 671 and 672 can allow access to the switch and/or venting holes of the pump exhaust.
A label 641 can be provided over the apertures 671 and 672 and positioned over the exposed portion of the electronic components 650. The label can include the vent holes 642, indicator portions 644, and/or switch cover 643. The indicator portions 644 can include holes or transparent regions 644 for positioning over the one or more indicators or LEDs on the printed circuit board 681 below the label 641. The holes or transparent regions 644 can allow for the indicators or LEDs to be visible through the label 641. In some embodiments, the switch cover 642 can include a dome shaped cover positioned over the switch on the printed circuit board 681. In some embodiments, the label 641 can include embossed features for the switch cover 642. In some embodiments, the embossed features of the switch cover 642 can prevent accidental activation or deactivation of the device. In some embodiments, the switch or switch cover 642 can include a tab on the switch to prevent accidental activation or deactivation. The vent holes 642 of the label can allow exhaust from the pump outlet mechanism to pass through the label and exit the wound dressing to be exhausted to the atmosphere.
In some embodiments, the label can be positioned on top of the cover layer or backing layer 613. The label can be sealed to the top surface of the cover layer. In other embodiments, the label 641 can be positioned above the overlay layer 671 and below the cover layer or backing layer 613. In such embodiments, the cover layer 613 can have one or more apertures over one or more components of the label 641. For example, the cover layer 613 can have apertures over the vent holes 642, indicator portions 644, and/or switch cover 643.
A label or covering 741 can be positioned over and cover the electronics and an opening 740 in the overlay layer 717 as shown in
The visual indicators 744 can provide an indication of operation of the negative pressure source and/or an indication of the level of negative pressure that is applied to the wound. In some embodiments, the visual indicators can include one or more light sources or LEDs. In some embodiments, the visual indicator light sources an illuminate to indicate a condition or change of condition. In some embodiments, the light source can illuminate in a particular sequence and/or color that indicates a condition. For example, in some embodiments, the light source can flash to notify the user that the device is operating properly. In some embodiments, the light source can automatically flash periodically and/or the light source can be activated by the switch or other button to light up and indicate a condition.
In some embodiments, the switch can be pressed and/or held down to power the dressing and electronics on and off. In some embodiments, once the switch is activated and the pump and associated colored LED, for example, green colored LED, can be used to conformed the dressing and integrated negative pressure source is operational. In some embodiments, during operation of the pump and dressing, the pump and dressing can enter the fault state indicated by a colored LED, for example, orange colored LED.
The electronics components can be incorporated in the dressing. For example, the dressing components can be assembled to form one integrated negative pressure dressing to be positioned over a wound. The following assembly description describes an embodiment of the assembly of an integrated wound dressing. In some embodiments, some or all of the assembly process can be automated and/or any or all of the processes or procedures can be done in any order.
A transmission layer can be positioned over the wound contact layer as shown in
The overlay layer 717 can be positioned over the apertured pads or absorbent material with the aperture in the overlay layer positioned over the switch of the electronics assembly. In some embodiments, the edges and/or the outer perimeter of the overlay layer 717 can be adhered or secured to the top or upper surface of the wound contact layer 710. A top film or cover layer can be placed over the overlay layer 717 as shown in
A label cover can be applied over the switch and/or other components of the electronics assembly that are exposed through the apertures of the overlay layer 717 and the cover layer. The indicator portions can include transparent portions or LED windows aligned with the LED's on the PCB when the label cover is applied. In some embodiments, the LED windows can include apertures in the label cover. In other embodiments, the LED windows can be transparent portions of the label cover. The exhaust holes can also be aligned with apertures in the label cover.
Before use, the dressing can include a delivery layer 945 adhered to the bottom surface of the wound contact layer. The delivery layer 945 can cover adhesive or apertures on the bottom surface of the wound contact layer 910. In some embodiments, the delivery layer 945 can provided support for the dressing and can assist in sterile and appropriate placement of the dressing over the wound and skin of the patient. The delivery layer 945 can include handles 946 that can be used by the user to separate the delivery layer 945 from the wound contact layer 910 before applying the dressing 900 to a wound and skin of a patient.
The wound dressing with embedded electronics can be any shape or size to accommodate various types of wounds. For example, the wound dressing with embedded electronics can have a rectangular, rounded rectangular, square, T shaped, or any other shape or design. In some embodiments, the wound dressings with embedded electronics described herein can be rectangular or rounded rectangular shaped as illustrated with reference to
All of the features disclosed in this specification (including any accompanying exhibits, claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The disclosure is not restricted to the details of any foregoing embodiments. The disclosure extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
Various modifications to the implementations described in this disclosure may be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other implementations without departing from the spirit or scope of this disclosure. Thus, the disclosure is not intended to be limited to the implementations shown herein, but is to be accorded the widest scope consistent with the principles and features disclosed herein. Certain embodiments of the disclosure are encompassed in the claim set listed below or presented in the future.
This application is a continuation of U.S. application Ser. No. 16/338,400, filed Mar. 29, 2019, which is a U.S. national stage application of International Patent Application No. PCT/EP2017/074764, filed on Sep. 29, 2017, which claims priority to U.S. Provisional Application No. 62/558,263, filed Sep. 13, 2017, U.S. Provisional Application No. 62/402,551, filed Sep. 30, 2016.
Number | Name | Date | Kind |
---|---|---|---|
3874387 | Barbieri | Apr 1975 | A |
4224941 | Stivala | Sep 1980 | A |
4398910 | Blake et al. | Aug 1983 | A |
4534356 | Papadakis | Aug 1985 | A |
4569674 | Phillips et al. | Feb 1986 | A |
4624656 | Clark et al. | Nov 1986 | A |
4681562 | Beck et al. | Jul 1987 | A |
4767943 | Adler et al. | Aug 1988 | A |
4979944 | Luzsicza | Dec 1990 | A |
5055195 | Trasch et al. | Oct 1991 | A |
5055198 | Shettigar | Oct 1991 | A |
5056510 | Gilman | Oct 1991 | A |
5152757 | Eriksson | Oct 1992 | A |
5181905 | Flam | Jan 1993 | A |
5266928 | Johnson | Nov 1993 | A |
D357743 | Bilitz et al. | Apr 1995 | S |
5527293 | Zamierowski | Jun 1996 | A |
5549584 | Gross | Aug 1996 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5643189 | Masini | Jul 1997 | A |
5779657 | Daneshvar | Jul 1998 | A |
5833646 | Masini | Nov 1998 | A |
5902256 | Benaron | May 1999 | A |
5964723 | Augustine | Oct 1999 | A |
6071267 | Zamierowski | Jun 2000 | A |
6142982 | Hunt et al. | Nov 2000 | A |
6168800 | Dobos et al. | Jan 2001 | B1 |
6183438 | Berguer | Feb 2001 | B1 |
6225523 | Masini | May 2001 | B1 |
6261276 | Reitsma | Jul 2001 | B1 |
6261283 | Morgan et al. | Jul 2001 | B1 |
6377848 | Garde et al. | Apr 2002 | B1 |
6398767 | Fleischmann | Jun 2002 | B1 |
6458109 | Henley et al. | Oct 2002 | B1 |
6471982 | Lydon et al. | Oct 2002 | B1 |
6599262 | Masini | Jul 2003 | B1 |
6607495 | Skalak et al. | Aug 2003 | B1 |
6685681 | Lockwood et al. | Feb 2004 | B2 |
6787682 | Gilman | Sep 2004 | B2 |
6794554 | Sessions et al. | Sep 2004 | B2 |
6800074 | Henley et al. | Oct 2004 | B2 |
6855135 | Lockwood et al. | Feb 2005 | B2 |
6942633 | Odland | Sep 2005 | B2 |
6951553 | Bubb et al. | Oct 2005 | B2 |
6979324 | Bybordi et al. | Dec 2005 | B2 |
7004915 | Boynton et al. | Feb 2006 | B2 |
7022113 | Lockwood et al. | Apr 2006 | B2 |
7067709 | Murata et al. | Jun 2006 | B2 |
7070584 | Johnson et al. | Jul 2006 | B2 |
7087806 | Scheinberg et al. | Aug 2006 | B2 |
7108683 | Zamierowski | Sep 2006 | B2 |
7338482 | Lockwood et al. | Mar 2008 | B2 |
7361184 | Joshi | Apr 2008 | B2 |
7524315 | Blott et al. | Apr 2009 | B2 |
7553306 | Hunt et al. | Jun 2009 | B1 |
7611500 | Lina et al. | Nov 2009 | B1 |
7615036 | Joshi et al. | Nov 2009 | B2 |
D605775 | Koch et al. | Dec 2009 | S |
D608007 | Arbesman et al. | Jan 2010 | S |
7645253 | Gura et al. | Jan 2010 | B2 |
7687678 | Jacobs | Mar 2010 | B2 |
7699823 | Haggstrom et al. | Apr 2010 | B2 |
7776028 | Miller et al. | Aug 2010 | B2 |
D625422 | Arbesman et al. | Oct 2010 | S |
7815616 | Boehringer et al. | Oct 2010 | B2 |
7837673 | Vogel | Nov 2010 | B2 |
7846141 | Weston | Dec 2010 | B2 |
7896864 | Lockwood et al. | Mar 2011 | B2 |
7922676 | Daskal et al. | Apr 2011 | B2 |
7922703 | Riesinger | Apr 2011 | B2 |
7942866 | Radl et al. | May 2011 | B2 |
7959624 | Riesinger | Jun 2011 | B2 |
7976519 | Bubb et al. | Jul 2011 | B2 |
8007257 | Heaton et al. | Aug 2011 | B2 |
8007481 | Schuessler et al. | Aug 2011 | B2 |
8062272 | Weston | Nov 2011 | B2 |
8080702 | Blott et al. | Dec 2011 | B2 |
8092441 | Sugito | Jan 2012 | B2 |
8158844 | McNeil | Apr 2012 | B2 |
8167869 | Wudyka | May 2012 | B2 |
8212100 | Moore | Jul 2012 | B2 |
8215929 | Shen et al. | Jul 2012 | B2 |
8323264 | Weston et al. | Dec 2012 | B2 |
8371829 | Jaeb et al. | Feb 2013 | B2 |
8372049 | Jaeb et al. | Feb 2013 | B2 |
8372050 | Jaeb et al. | Feb 2013 | B2 |
8404921 | Lee et al. | Mar 2013 | B2 |
8409160 | Locke et al. | Apr 2013 | B2 |
8414519 | Hudspeth et al. | Apr 2013 | B2 |
8419696 | Wilkes | Apr 2013 | B2 |
8425478 | Olson | Apr 2013 | B2 |
8439894 | Miller | May 2013 | B1 |
8449508 | Coulthard et al. | May 2013 | B2 |
8500776 | Ebner | Aug 2013 | B2 |
8529548 | Blott et al. | Sep 2013 | B2 |
8545466 | Andresen et al. | Oct 2013 | B2 |
8579872 | Coulthard et al. | Nov 2013 | B2 |
8603074 | Kagan | Dec 2013 | B2 |
8604265 | Locke et al. | Dec 2013 | B2 |
8641691 | Fink et al. | Feb 2014 | B2 |
8641693 | Locke et al. | Feb 2014 | B2 |
8702665 | Locke et al. | Apr 2014 | B2 |
8764732 | Hartwell | Jul 2014 | B2 |
8795257 | Coulthard et al. | Aug 2014 | B2 |
8814842 | Coulthard et al. | Aug 2014 | B2 |
8821458 | Locke et al. | Sep 2014 | B2 |
8870837 | Locke et al. | Oct 2014 | B2 |
8961496 | Locke et al. | Feb 2015 | B2 |
8974429 | Gordon et al. | Mar 2015 | B2 |
9061095 | Adie et al. | Jun 2015 | B2 |
9084845 | Adie et al. | Jul 2015 | B2 |
9089630 | Perkins et al. | Jul 2015 | B2 |
9198802 | Robinson et al. | Dec 2015 | B2 |
9259558 | Tsai | Feb 2016 | B2 |
9265665 | Robinson et al. | Feb 2016 | B2 |
9283118 | Locke et al. | Mar 2016 | B2 |
9393354 | Freedman et al. | Jul 2016 | B2 |
9414968 | Heagle | Aug 2016 | B2 |
9421133 | Hu et al. | Aug 2016 | B2 |
9427505 | Askem et al. | Aug 2016 | B2 |
9452088 | Shulman et al. | Sep 2016 | B2 |
9560975 | Mei et al. | Feb 2017 | B2 |
D787690 | Mackay et al. | May 2017 | S |
9737649 | Begin et al. | Aug 2017 | B2 |
9770368 | Robinson et al. | Sep 2017 | B2 |
9814811 | Aalders et al. | Nov 2017 | B2 |
9907703 | Allen et al. | Mar 2018 | B2 |
9925092 | Luckemeyer et al. | Mar 2018 | B2 |
RE46778 | Peron | Apr 2018 | E |
9956120 | Locke | May 2018 | B2 |
10004914 | Nettesheim et al. | Jun 2018 | B2 |
10016544 | Coulthard et al. | Jul 2018 | B2 |
10046095 | Middaugh et al. | Aug 2018 | B1 |
10086117 | Locke et al. | Oct 2018 | B2 |
11564847 | Beadle | Jan 2023 | B2 |
20030183659 | Van Zeeland et al. | Oct 2003 | A1 |
20030212357 | Pace | Nov 2003 | A1 |
20040076662 | Riesinger | Apr 2004 | A1 |
20040087884 | Haddock et al. | May 2004 | A1 |
20040167482 | Watson | Aug 2004 | A1 |
20050012616 | Forster et al. | Jan 2005 | A1 |
20050045461 | Sweetland et al. | Mar 2005 | A1 |
20050065471 | Kuntz | Mar 2005 | A1 |
20050119737 | Bene et al. | Jun 2005 | A1 |
20050137539 | Biggie et al. | Jun 2005 | A1 |
20060029650 | Coffey | Feb 2006 | A1 |
20060086598 | Sneek et al. | Apr 2006 | A1 |
20060107642 | Smith et al. | May 2006 | A1 |
20060259102 | Slatkine | Nov 2006 | A1 |
20070055209 | Patel et al. | Mar 2007 | A1 |
20070066946 | Haggstrom et al. | Mar 2007 | A1 |
20070128055 | Lee | Jun 2007 | A1 |
20070179460 | Adahan | Aug 2007 | A1 |
20070225663 | Watt et al. | Sep 2007 | A1 |
20070255187 | Branch | Nov 2007 | A1 |
20080021356 | Castello Escude | Jan 2008 | A1 |
20080051716 | Stutz | Feb 2008 | A1 |
20090012484 | Nielsen et al. | Jan 2009 | A1 |
20090048556 | Durand | Feb 2009 | A1 |
20100022990 | Karpowicz et al. | Jan 2010 | A1 |
20100100160 | Edman et al. | Apr 2010 | A1 |
20100137775 | Hu et al. | Jun 2010 | A1 |
20100160881 | Lin et al. | Jun 2010 | A1 |
20100207768 | Pidgeon et al. | Aug 2010 | A1 |
20100280469 | Hall et al. | Nov 2010 | A1 |
20100292632 | Mulvihill et al. | Nov 2010 | A1 |
20110028918 | Hartwell | Feb 2011 | A1 |
20110092927 | Wilkes et al. | Apr 2011 | A1 |
20110112492 | Bharti et al. | May 2011 | A1 |
20110224631 | Simmons et al. | Sep 2011 | A1 |
20110292623 | Stanley | Dec 2011 | A1 |
20110305736 | Wieland et al. | Dec 2011 | A1 |
20120016323 | Robinson et al. | Jan 2012 | A1 |
20120051018 | Øllgaard | Mar 2012 | A1 |
20120059294 | Schubert et al. | Mar 2012 | A1 |
20120109034 | Locke et al. | May 2012 | A1 |
20120109083 | Coulthard | May 2012 | A1 |
20120325215 | Levenick et al. | Dec 2012 | A1 |
20130215638 | Dabov et al. | Aug 2013 | A1 |
20130317406 | Locke et al. | Nov 2013 | A1 |
20140100536 | Angel | Apr 2014 | A1 |
20140343518 | Riesinger | Nov 2014 | A1 |
20150057625 | Coulthard | Feb 2015 | A1 |
20150065965 | Haggstrom et al. | Mar 2015 | A1 |
20150174304 | Askem | Jun 2015 | A1 |
20150182677 | Collinson et al. | Jul 2015 | A1 |
20150202354 | Wall | Jul 2015 | A1 |
20150216733 | Allen et al. | Aug 2015 | A1 |
20160015873 | Robinson et al. | Jan 2016 | A1 |
20160166438 | Rovaniemi | Jun 2016 | A1 |
20160199546 | Chao | Jul 2016 | A1 |
20160242964 | Rapp et al. | Aug 2016 | A1 |
20160270967 | Hartwell | Sep 2016 | A1 |
20160271305 | Kurihara et al. | Sep 2016 | A1 |
20160361473 | Robinson et al. | Dec 2016 | A1 |
20170112974 | Fujisaki | Apr 2017 | A1 |
20170112975 | Fujisaki | Apr 2017 | A1 |
20170127525 | Schonholz | May 2017 | A1 |
20170232189 | Qin et al. | Aug 2017 | A1 |
20170296714 | Locke et al. | Oct 2017 | A1 |
20170319761 | Locke et al. | Nov 2017 | A1 |
20170326277 | Huang | Nov 2017 | A1 |
20170368239 | Askem et al. | Dec 2017 | A1 |
20180008760 | Zilbershlag et al. | Jan 2018 | A1 |
20180021178 | Locke | Jan 2018 | A1 |
20180028728 | Aarestad et al. | Feb 2018 | A1 |
20180104393 | Wu et al. | Apr 2018 | A1 |
20180200414 | Askem et al. | Jul 2018 | A1 |
20180272052 | Locke et al. | Sep 2018 | A1 |
20180318137 | Donda et al. | Nov 2018 | A1 |
20180318165 | Donda et al. | Nov 2018 | A1 |
20180353771 | Kim et al. | Dec 2018 | A1 |
20190021911 | Askem et al. | Jan 2019 | A1 |
20190125943 | Askem et al. | May 2019 | A1 |
20190142644 | Askem et al. | May 2019 | A1 |
20190143007 | Askem et al. | May 2019 | A1 |
20190159938 | Askem et al. | May 2019 | A1 |
20190192350 | Gowans et al. | Jun 2019 | A1 |
20190298580 | Hall | Oct 2019 | A1 |
20210001022 | Lin | Jan 2021 | A1 |
Number | Date | Country |
---|---|---|
201664463 | Dec 2010 | CN |
19844355 | Apr 2000 | DE |
0512543 | Nov 1992 | EP |
1411874 | Apr 2004 | EP |
1455701 | Mar 2006 | EP |
1807032 | Jul 2007 | EP |
1476217 | Mar 2008 | EP |
1976477 | Oct 2008 | EP |
1507498 | Jul 2009 | EP |
1791579 | Jul 2009 | EP |
2109472 | Oct 2009 | EP |
1947987 | May 2010 | EP |
1358456 | Jul 2010 | EP |
2214728 | Aug 2010 | EP |
2279016 | Feb 2011 | EP |
2326295 | Jun 2011 | EP |
2340064 | Jul 2011 | EP |
2346468 | Jul 2011 | EP |
2349155 | Aug 2011 | EP |
2205190 | Sep 2011 | EP |
2370116 | Oct 2011 | EP |
2531761 | Dec 2012 | EP |
2231088 | Jan 2013 | EP |
2015655 | Mar 2013 | EP |
2285323 | Mar 2013 | EP |
2563421 | Mar 2013 | EP |
2049055 | Apr 2013 | EP |
2340066 | Apr 2013 | EP |
2440260 | May 2013 | EP |
2340062 | Jun 2013 | EP |
2603699 | Jun 2013 | EP |
1893145 | Jul 2013 | EP |
2370142 | Jul 2013 | EP |
2279017 | Aug 2013 | EP |
2370117 | Aug 2013 | EP |
2258443 | Sep 2013 | EP |
2263742 | Sep 2013 | EP |
2659915 | Nov 2013 | EP |
1848390 | Dec 2013 | EP |
1875081 | Dec 2013 | EP |
2271381 | Dec 2013 | EP |
2160166 | Jan 2014 | EP |
1565219 | Feb 2014 | EP |
2305325 | Apr 2014 | EP |
2323712 | Apr 2014 | EP |
2451498 | Apr 2014 | EP |
2051675 | Jun 2014 | EP |
1485613 | Jul 2014 | EP |
1545644 | Aug 2014 | EP |
2349154 | Aug 2014 | EP |
2146759 | Sep 2014 | EP |
2416816 | Oct 2014 | EP |
2468323 | Oct 2014 | EP |
2658493 | Oct 2014 | EP |
1850818 | Dec 2014 | EP |
2268348 | Dec 2014 | EP |
2561128 | Jan 2015 | EP |
2829287 | Jan 2015 | EP |
2683285 | Feb 2015 | EP |
2470136 | Mar 2015 | EP |
2503974 | May 2015 | EP |
2249894 | Aug 2015 | EP |
2802366 | Aug 2015 | EP |
2438302 | Sep 2015 | EP |
2346545 | Oct 2015 | EP |
2438301 | Oct 2015 | EP |
2802304 | Dec 2015 | EP |
2852421 | Jan 2016 | EP |
2410962 | Mar 2016 | EP |
2640436 | Mar 2016 | EP |
2855937 | May 2016 | EP |
2433594 | Jun 2016 | EP |
2919730 | Jun 2016 | EP |
2861869 | Jul 2016 | EP |
2945584 | Jul 2016 | EP |
2293749 | Aug 2016 | EP |
2305327 | Oct 2016 | EP |
2467086 | Oct 2016 | EP |
2470135 | Oct 2016 | EP |
2767305 | Oct 2016 | EP |
2282788 | Dec 2016 | EP |
2462956 | Mar 2017 | EP |
3139878 | Mar 2017 | EP |
2249761 | Apr 2017 | EP |
1587502 | May 2017 | EP |
1587554 | May 2017 | EP |
2731563 | May 2017 | EP |
2968871 | Jul 2017 | EP |
2632613 | Aug 2017 | EP |
2781208 | Aug 2017 | EP |
2888478 | Aug 2017 | EP |
2937107 | Aug 2017 | EP |
2967627 | Aug 2017 | EP |
3062751 | Aug 2017 | EP |
3139879 | Aug 2017 | EP |
2359784 | Sep 2017 | EP |
3151795 | Sep 2017 | EP |
2367518 | Oct 2017 | EP |
2675493 | Oct 2017 | EP |
3068455 | Oct 2017 | EP |
2558046 | Nov 2017 | EP |
2736548 | Nov 2017 | EP |
3052158 | Nov 2017 | EP |
2593058 | Mar 2018 | EP |
3139880 | Mar 2018 | EP |
1496822 | Aug 2018 | EP |
2879633 | Aug 2018 | EP |
2227203 | Sep 2018 | EP |
2696826 | Sep 2018 | EP |
3106186 | Sep 2018 | EP |
3162330 | Sep 2018 | EP |
3169382 | Sep 2018 | EP |
3203953 | Sep 2018 | EP |
2941280 | Oct 2018 | EP |
3244852 | Oct 2018 | EP |
2687241 | Nov 2018 | EP |
2687243 | Nov 2018 | EP |
3062753 | Nov 2018 | EP |
3120879 | Dec 2018 | EP |
3191149 | Jan 2019 | EP |
2370130 | Mar 2019 | EP |
3053609 | Mar 2019 | EP |
3180048 | Mar 2019 | EP |
3143974 | Apr 2019 | EP |
2285432 | Jun 2019 | EP |
3050545 | Jul 2019 | EP |
3319656 | Aug 2019 | EP |
2355762 | Sep 2019 | EP |
2822613 | Sep 2019 | EP |
2863855 | Sep 2019 | EP |
2482912 | Oct 2019 | EP |
3038667 | Oct 2019 | EP |
3129095 | Oct 2019 | EP |
3191150 | Oct 2019 | EP |
3280466 | Oct 2019 | EP |
2244756 | Dec 2019 | EP |
2968702 | Dec 2019 | EP |
2939320 | Jun 2010 | FR |
2511523 | Sep 2014 | GB |
H04354722 | Dec 1992 | JP |
131622 | Aug 2013 | RU |
WO-2009098696 | Aug 2009 | WO |
WO-2009120951 | Oct 2009 | WO |
WO-2011130570 | Oct 2011 | WO |
WO-2011135285 | Nov 2011 | WO |
WO-2011144888 | Nov 2011 | WO |
WO-2013136181 | Sep 2013 | WO |
WO-2014099709 | Jun 2014 | WO |
WO-2015116823 | Aug 2015 | WO |
WO-2016126560 | Aug 2016 | WO |
WO-2016174048 | Nov 2016 | WO |
WO-2017079174 | May 2017 | WO |
WO-2017196888 | Nov 2017 | WO |
WO-2018056060 | Mar 2018 | WO |
WO-2018060412 | Apr 2018 | WO |
WO-2018060417 | Apr 2018 | WO |
WO-2018115461 | Jun 2018 | WO |
WO-2018156730 | Aug 2018 | WO |
WO-2018158250 | Sep 2018 | WO |
WO-2018162613 | Sep 2018 | WO |
WO-2018164803 | Sep 2018 | WO |
WO-2018185138 | Oct 2018 | WO |
WO-2018192978 | Oct 2018 | WO |
WO-2018206420 | Nov 2018 | WO |
WO-2019053101 | Mar 2019 | WO |
WO-2019053106 | Mar 2019 | WO |
Entry |
---|
International Preliminary Report on Patentability for Application No. PCT/EP2017/074755, mailed on Apr. 11, 2019, 10 pages. |
International Preliminary Report on Patentability for Application No. PCT/EP2017/074764, mailed on Apr. 11, 2019, 9 pages. |
International Search Report and Written Opinion for Application No. PCT/EP2017/074755, mailed on Jan. 2, 2018, 12 pages. |
International Search Report and Written Opinion for Application No. PCT/EP2017/074764, mailed on Jan. 2, 2018, 12 pages. |
Number | Date | Country | |
---|---|---|---|
20230248578 A1 | Aug 2023 | US |
Number | Date | Country | |
---|---|---|---|
62558263 | Sep 2017 | US | |
62402551 | Sep 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16338400 | US | |
Child | 18096937 | US |